Lyell Immunopharma, Inc. $LYEL Shares Sold by TD Asset Management Inc

TD Asset Management Inc lessened its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 95.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,232 shares of the company’s stock after selling 954,410 shares during the quarter. TD Asset Management Inc’s holdings in Lyell Immunopharma were worth $444,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of LYEL. Almitas Capital LLC lifted its holdings in Lyell Immunopharma by 136.3% during the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after buying an additional 1,432,086 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after buying an additional 443,614 shares during the last quarter. Nuveen LLC bought a new position in Lyell Immunopharma during the 1st quarter worth approximately $345,000. Finally, AQR Capital Management LLC lifted its holdings in Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. One research analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Lyell Immunopharma presently has a consensus rating of “Sell” and a consensus price target of $15.00.

Lyell Immunopharma Trading Up 7.6%

Shares of NASDAQ LYEL opened at $18.32 on Friday. The company has a market cap of $351.95 million, a price-to-earnings ratio of -0.75 and a beta of -0.07. Lyell Immunopharma, Inc. has a 12-month low of $7.65 and a 12-month high of $30.00. The stock’s 50 day simple moving average is $13.97 and its 200 day simple moving average is $11.07.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.80) by $0.91. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%. As a group, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.